Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $60.08M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.60M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
Intrinsic Alpha fair value
Locked
Current Price
$1.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Relmada Therapeutics, Inc. NASDAQ:RLMD | $449.08M | $4.21 | Not rated | -9.6 | -25.60% |
Immunic, Inc. NASDAQ:IMUX | $102.61M | $7.52 | Not rated | -4.1 | +3.65% |
Unicycive Therapeutics, Inc. NASDAQ:UNCY | $97.25M | $3.55 | Not rated | -40.8 | -36.17% |
Vaxart, Inc. NASDAQ:VXRT | $90.17M | $0.37 | Undervalued | 3.6 | +36.97% |
Cibus, Inc. NASDAQ:CBUS | $86.36M | $1.13 | Not rated | -8.6 | -3.15% |
PMV Pharmaceuticals, Inc. NASDAQ:PMVP | $67.73M | $1.27 | Not rated | -0.8 | -3.68% |
Biomea Fusion, Inc. NASDAQ:BMEA | $42.31M | $0.58 | Not rated | -1.9 | -33.13% |
aTyr Pharma, Inc. NASDAQ:ATYR | $14.97M | $6.11 | Not rated | -0.7 | -21.25% |
TScan Therapeutics, Inc. NASDAQ:TCRX | $10.20M | $0.16 | Not rated | -1.0 | -19.93% |
Continue the stock analysis
Jump to another research area for this company.